P11.17 Splicing dysregulation drives glioblastoma malignancy: SRSF3 as a potential therapeutic target to impair glioblastoma progression

Glioblastomas (GBMs) remain the deadliest human brain tumors, with poor prognosis despite years of research. Currently, standard therapeutic strategies to treat GBM are not efficient and common survival from diagnosis is ~12–16 months. Thus, identification of new diagnostic/prognostic/therapeutic to...

Full description

Saved in:
Bibliographic Details
Published in:Neuro Oncol
Main Authors: Fuentes-Fayos, A C, Vázquez-Borrego, M C, Jiménez-Vacas, J M, Bejarano, L, Blanco-Acevedo, C, Sánchez-Sánchez, R, Solivera, J, Blasco, M A, Castaño, J P, Luque, R M
Format: Artigo
Language:Inglês
Published: Oxford University Press 2019
Subjects:
Poster Presentations
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6796159/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz126.163
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items